STAT+: ARCH-launched Neumora stops depression program

STAT PlusNewsletterThe Readout ARCH-launched Neumora stops depression program A new AI model to improve trial enrollment, importing drugs from Canada, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Elaine ChenJune 16, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get straight to the news today.Advertisement The need-to-know this morning Moderna said Ester Banque joined the company as chief commercial officer. She was formerly president of U.S. operations for Zoetis. Moderna President Stephen Hoge has also been given an expanded role overseeing several of the company’s drug development programs. New AI model aims to improve trial enrollment The biotech Verge Labs today released a new AI model that it says will help determine which patients will respond to treatment better, leading to fewer people dropping out while also increasing the statistical power of a trial. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech June 16, 2026 STAT Plus: Verge Labs’ new AI model solves patient stratification problems for neurology clinical trials Politics June 15, 2026 STAT Plus: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end Advertisement Health June 15, 2026 Covid vaccination cut risk of adverse heart events, large study finds The Readout June 15, 2026 STAT Plus: Lilly’s Ajax acquisition may have been worth it The Readout June 12, 2026 STAT Plus: Prometheus raises $12 billion in capital for artificial engineers Subscriber Picks